RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
HOUSTON ― The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial,...















